Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model

Cost-utility analysis of Palbociclib + letrozole and ribociclib + letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model

Abstract Background Palbociclib and Ribociclib are cyclin-dependent kinase 4/6 oral molecular inhibitors that have the potential to improve overall survival (OS), progression-free survival (PFS), and quality of life in patients with metastatic breast cancer (MBC). The objective of this study was to...

Full description

Bibliographic Details
Main Authors: Ali Darvishi, Rajabali Daroudi, Ali Akbar Fazaeli
Format: Article
Language:English
Published: BMC 2023-11-01
Series:Health Economics Review
Subjects:
Cost-utility analysis
Palbociclib
Riboociclib
Letrozole
Metastatic breast cancer
HR+/ HER2
Online Access:https://doi.org/10.1186/s13561-023-00463-6

Internet

https://doi.org/10.1186/s13561-023-00463-6

Similar Items